Euroapi
Euroapi, a leading player in the pharmaceutical industry, is headquartered in France and operates across major regions in Europe and beyond. Founded in 2022, the company has quickly established itself as a key provider of active pharmaceutical ingredients (APIs) and advanced drug delivery systems. With a focus on innovation and sustainability, Euroapi offers a diverse range of products and services that cater to the evolving needs of the healthcare sector. Their commitment to quality and regulatory compliance sets them apart in a competitive market. Recognised for their expertise in complex APIs, Euroapi has achieved significant milestones, positioning itself as a trusted partner for pharmaceutical companies worldwide. As the industry continues to evolve, Euroapi remains dedicated to advancing healthcare solutions through cutting-edge technology and strategic collaborations.
DitchCarbon Score
How does Euroapi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Euroapi's score of 55 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Euroapi's reported carbon emissions
In 2024, Euroapi reported total carbon emissions of approximately 96,472,000 kg CO2e, a decrease from about 107,454,000 kg CO2e in 2023. The emissions for 2022 were about 91,700,000 kg CO2e, with a breakdown of 91,700,000 kg CO2e for Scope 1 and 63,086,000 kg CO2e for Scope 2. The company has not disclosed specific Scope 3 emissions for 2023 and 2024, but in 2022, Scope 3 emissions were approximately 40,003,000 kg CO2e. Euroapi has set ambitious climate commitments, aiming for a 30% reduction in Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. This target translates to a reduction of about 30% from the 101,300,000 kg CO2e reported in 2020. Additionally, the company has established a more aggressive goal of achieving a 42% reduction in Scope 1 and Scope 2 emissions by 2030, compared to 2022 levels. Looking further ahead, Euroapi has committed to achieving net-zero carbon emissions by 2050, with a target of reducing overall emissions (Scope 1, 2, and 3) by 90% from 2022 levels by 2050. These initiatives reflect Euroapi's dedication to sustainability and its proactive approach to addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 91,378,000 | 000,000,000 | 00,000,000 | - | - |
| Scope 2 | 74,043,000 | 00,000,000 | 00,000,000 | - | - |
| Scope 3 | 705,065,000 | 000,000,000 | 00,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Euroapi is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
